{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:01:29Z","timestamp":1790557289015,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA-BC010313"],"award-info":[{"award-number":["ZIA-BC010313"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajpath.2024.10.013","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T18:13:42Z","timestamp":1731262422000},"page":"362-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Genetic, Epigenetic, and Microenvironmental Drivers of Cholangiocarcinoma"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9271-016X","authenticated-orcid":false,"given":"Vijay","family":"Putatunda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-7771","authenticated-orcid":false,"given":"Apinya","family":"Jusakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2024.10.013_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ijc.35034","article-title":"The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand","volume":"155","author":"Pupacdi","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/0284186X.2019.1590634","article-title":"Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study","volume":"58","author":"Strijker","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib4","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejso.2019.04.002","article-title":"Increased multimodality treatment options has improved survival for hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged","volume":"45","author":"Alabraba","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2188\/jea.JE20180007","article-title":"Cholangiocarcinoma trends, incidence, and relative survival in Khon Kaen, Thailand from 1989 through 2013: a population-based cancer registry study","volume":"29","author":"Kamsa-ard","year":"2019","journal-title":"J Epidemiol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.hpb.2023.07.898","article-title":"Intrahepatic cholangiocarcinoma: how do hepatectomy outcomes compare to liver metastases and hepatocellular carcinoma?","volume":"25","author":"Diggs","year":"2023","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ajpath.2024.10.013_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.10.013_bib9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.bbadis.2017.06.014","article-title":"Epigenome dysregulation in cholangiocarcinoma","volume":"1864","author":"O'Rourke","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.ajpath.2024.10.013_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hep.31410","article-title":"The tumor microenvironment in cholangiocarcinoma progression","volume":"73","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib11","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2024.10.013_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.013_bib13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke\u2013related and non-infection-related bile duct cancers","volume":"45","author":"Chan-on","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2024.10.013_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.10.013_bib15","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.ajpath.2024.10.013_bib16","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.10.013_bib17","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI27282","article-title":"Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice","volume":"116","author":"Xu","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.10.013_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ajpath.2024.10.013_bib20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2021.11.010","article-title":"Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis","volume":"76","author":"Liu","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000530700","article-title":"Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management","volume":"13","author":"Ye","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","article-title":"Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes","volume":"35","author":"Xue","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.10.013_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.7150\/thno.63417","article-title":"Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ajpath.2024.10.013_bib25","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.18632\/oncotarget.1943","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajpath.2024.10.013_bib26","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.013_bib27","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.10.013_bib28","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.10.013_bib29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke\u2013associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2024.10.013_bib30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.31110","article-title":"Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities","volume":"72","author":"Goeppert","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/path.5994","article-title":"Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis","volume":"258","author":"Kamp","year":"2022","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib32","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep4.1730","article-title":"DNA methylation markers for detection of cholangiocarcinoma: discovery, validation, and clinical testing in biliary brushings and plasma","volume":"5","author":"Yang","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2024.10.013_bib33","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/gutjnl-2023-330483","article-title":"Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies","volume":"73","author":"Hong","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2024.10.013_bib34","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2024.10.013_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.10.013_bib36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.29764","article-title":"Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma","volume":"68","author":"Nepal","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib37","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2024.10.013_bib38","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.3390\/ijms25137337","article-title":"Molecular targeting of the isocitrate dehydrogenase pathway and the implications for cancer therapy","volume":"25","author":"Ivanov","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2024.10.013_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting [alpha]-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.10.013_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep"},{"key":"10.1016\/j.ajpath.2024.10.013_bib41","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib42","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/hep.26721","article-title":"Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway","volume":"59","author":"Goeppert","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2017.02.017","article-title":"SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma","volume":"67","author":"Merino-Azpitarte","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2023.02.039","article-title":"MYC determines lineage commitment in KRAS-driven primary liver cancer development","volume":"79","author":"D'Artista","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib45","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050358","article-title":"Smad4 restricts injury-provoked biliary proliferation and carcinogenesis","volume":"17","author":"Alexander","year":"2024","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ajpath.2024.10.013_bib46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s44319-024-00075-z","article-title":"TGFbeta-induced long non-coding RNA LINC00313 activates Wnt signaling and promotes cholangiocarcinoma","volume":"25","author":"Papoutsoglou","year":"2024","journal-title":"EMBO Rep"},{"key":"10.1016\/j.ajpath.2024.10.013_bib47","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41417-024-00726-2","article-title":"LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2\/STAT3 signaling","volume":"31","author":"Yu","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ajpath.2024.10.013_bib48","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.7150\/ijbs.66224","article-title":"YY1-induced DLEU1\/miR-149-5p promotes malignant biological behavior of cholangiocarcinoma through upregulating YAP1\/TEAD2\/SOX2","volume":"18","author":"Li","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.ajpath.2024.10.013_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12943-024-01950-y","article-title":"CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41419-022-04534-0","article-title":"Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ajpath.2024.10.013_bib51","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1053\/j.gastro.2006.02.057","article-title":"Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines","volume":"130","author":"Meng","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib52","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.gastro.2012.03.045","article-title":"MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin","volume":"143","author":"Zhang","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hep.29116","article-title":"MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib54","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/hep.22838","article-title":"MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3","volume":"49","author":"Selaru","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib55","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1002\/jcb.27286","article-title":"miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1","volume":"119","author":"Wan","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ajpath.2024.10.013_bib56","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/hep.25890","article-title":"Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma","volume":"56","author":"Oishi","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib57","first-page":"4684","article-title":"MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/bjc.2017.401","article-title":"Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma","volume":"118","author":"Kitano","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib59","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","article-title":"Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"75","author":"Ma","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib60","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/s41467-022-35291-5","article-title":"Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.10.013_bib61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jhep.2016.08.012","article-title":"Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages","volume":"66","author":"Raggi","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib62","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/0008-5472.CAN-12-2130","article-title":"Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma","volume":"73","author":"Mertens","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.10.013_bib63","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1002\/cam4.1704","article-title":"Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma","volume":"7","author":"Sha","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajpath.2024.10.013_bib64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-4598-9-13","article-title":"Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker","volume":"9","author":"Utispan","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib65","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3892\/ijo.2012.1530","article-title":"Periostin activates integrin [alpha]5[beta]1 through a PI3K\/AKT-dependent pathway in invasion of cholangiocarcinoma","volume":"41","author":"Utispan","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib66","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.10.013_bib67","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","article-title":"Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma","volume":"73","author":"Zhang","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib68","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/hep.24588","article-title":"Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells","volume":"54","author":"Fingas","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib69","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2018.12.004","article-title":"Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma","volume":"70","author":"Cadamuro","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib70","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jhep.2012.06.012","article-title":"Role of the stromal-derived factor-1 (SDF-1)\u2013CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma","volume":"57","author":"Gentilini","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.32099","article-title":"CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase","volume":"75","author":"Lin","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib72","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.neo.2019.10.005","article-title":"Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment","volume":"21","author":"Lin","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.ajpath.2024.10.013_bib73","first-page":"597","article-title":"Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma","volume":"3","author":"Subimerb","year":"2010","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ajpath.2024.10.013_bib74","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1349-7006.2010.01614.x","article-title":"Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma","volume":"101","author":"Hasita","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajpath.2024.10.013_bib75","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ccell.2017.05.006","article-title":"Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS","volume":"31","author":"Yuan","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.10.013_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001946","article-title":"Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3","volume":"9","author":"Zhou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib77","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI76452","article-title":"WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited","volume":"125","author":"Boulter","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.10.013_bib78","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.10.013_bib79","doi-asserted-by":"crossref","first-page":"18848","DOI":"10.1038\/s41598-020-75881-1","article-title":"Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles","volume":"10","author":"Bayik","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.10.013_bib80","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-20-0304","article-title":"Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.10.013_bib81","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/carcin\/bgt397","article-title":"CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils","volume":"35","author":"Zhou","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ajpath.2024.10.013_bib82","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41416-022-01838-y","article-title":"Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma","volume":"127","author":"Konishi","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib83","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2015.01.067","article-title":"Downregulation of FOXP3 inhibits invasion and immune escape in cholangiocarcinoma","volume":"458","author":"Ma","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajpath.2024.10.013_bib84","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2017.09.005","article-title":"Characterisation of the immune-related transcriptome in resected biliary tract cancers","volume":"86","author":"Ghidini","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib85","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","article-title":"Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"76","author":"Ding","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib86","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.32387","article-title":"Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression","volume":"76","author":"Luo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib87","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v4.24900","article-title":"Tumour cell\u2013derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth","volume":"4","author":"Haga","year":"2015","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.ajpath.2024.10.013_bib88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HEP.0000000000000437","article-title":"Bile exosomal miR-182\/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation","volume":"79","author":"Shu","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib89","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2022.11.025","article-title":"PTEN deficiency facilitates exosome secretion and metastasis in cholangiocarcinoma by impairing TFEB-mediated lysosome biogenesis","volume":"164","author":"Jiang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib90","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.bbadis.2015.06.024","article-title":"Proteomics profiling of cholangiocarcinoma exosomes: a potential role of oncogenic protein transferring in cancer progression","volume":"1852","author":"Dutta","year":"2015","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.ajpath.2024.10.013_bib91","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00018-022-04500-1","article-title":"BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner","volume":"79","author":"Liu","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ajpath.2024.10.013_bib92","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41417-022-00500-2","article-title":"Exosomal lncRNA HCG18 contributes to cholangiocarcinoma growth and metastasis through mediating miR-424-5p\/SOX9 axis through PI3K\/AKT pathway","volume":"30","author":"Ni","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ajpath.2024.10.013_bib93","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41420-022-00932-7","article-title":"Suppressive effects of umbilical cord mesenchymal stem cell-derived exosomal miR-15a-5p on the progression of cholangiocarcinoma by inhibiting CHEK1 expression","volume":"8","author":"Li","year":"2022","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.ajpath.2024.10.013_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23656","article-title":"Exosomal circ_0037104 derived from Hu-MSCs inhibits cholangiocarcinoma progression by sponging miR-620 and targeting AFAP1","volume":"38","author":"Yuan","year":"2024","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib95","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/cas.15644","article-title":"Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma","volume":"114","author":"Toshida","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajpath.2024.10.013_bib96","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1038\/s41598-023-34676-w","article-title":"Ceramide present in cholangiocarcinoma-derived extracellular vesicle induces a pro-inflammatory state in monocytes","volume":"13","author":"Oliviero","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.10.013_bib97","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.omtn.2022.12.012","article-title":"Exosomal circ-PTPN22 and circ-ADAMTS6 mark T cell exhaustion and neutrophil extracellular traps in Asian intrahepatic cholangiocarcinoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.ajpath.2024.10.013_bib98","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/hep.31493","article-title":"A circular RNA, cholangiocarcinoma-associated circular RNA 1, contributes to cholangiocarcinoma progression, induces angiogenesis, and disrupts vascular endothelial barriers","volume":"73","author":"Xu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib99","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/liv.15773","article-title":"Exosome-derived miR-182-5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK\/SEMA5a\/PI3K pathway","volume":"44","author":"Wang","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.ajpath.2024.10.013_bib100","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.7150\/ijbs.83170","article-title":"Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner","volume":"19","author":"Jiang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.ajpath.2024.10.013_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247798","article-title":"Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma","volume":"16","author":"Saab","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2024.10.013_bib102","doi-asserted-by":"crossref","first-page":"233","DOI":"10.31557\/APJCP.2021.22.1.233","article-title":"Profiling of bile microbiome identifies district microbial population between choledocholithiasis and cholangiocarcinoma patients","volume":"22","author":"Dangtakot","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ajpath.2024.10.013_bib103","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1038\/s41598-023-38307-2","article-title":"Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma","volume":"13","author":"Pomyen","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2024.10.013_bib104","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00535-024-02090-2","article-title":"Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma","volume":"59","author":"Xin","year":"2024","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib105","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2156255","article-title":"Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma","volume":"15","author":"Chai","year":"2023","journal-title":"Gut Microb"},{"key":"10.1016\/j.ajpath.2024.10.013_bib106","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/hep.30852","article-title":"Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma","volume":"71","author":"Jia","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.10.013_bib107","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4251\/wjgo.v16.i4.1319","article-title":"Causal roles of gut microbiota in cholangiocarcinoma etiology suggested by genetic study","volume":"16","author":"Chen","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.ajpath.2024.10.013_bib108","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajpath.2024.10.013_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome\u2013mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024004061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024004061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:08:18Z","timestamp":1772327298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944024004061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0002944024004061"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.10.013","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic, Epigenetic, and Microenvironmental Drivers of Cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}